Cancer Chemotherapy and Pharmacology

, Volume 65, Issue 3, pp 447–455 | Cite as

Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins

  • Özlem Darcansoy Işeri
  • Meltem Demirel Kars
  • Fikret Arpaci
  • Ufuk Gündüz
Original Article



Since multidrug resistance is a multifactorial phenomenon, a large-scale expression analysis of drug-resistant cells by using high-density oligonucleotide microarrays may provide information about new candidate genes contributing to resistance. Extracellular matrix (ECM) is responsible for many aspects of proliferation and invasive/metastatic behavior of tumor cells. This study demonstrates alterations in gene expression levels of several ECM components, matrix metalloproteinases (MMPs), adamalysins (ADAMs and ADAMTSs) and tissue inhibitors of metalloproteinases (TIMPs) in paclitaxel, docetaxel, vincristine and doxorubicin-resistant MCF-7 cells.


Resistant MCF-7 cells were developed by stepwise selection of cells in increasing concentrations of drugs. Affymetrix GeneChip® Human Genome U133 Plus 2.0 Array was used for hybridizations. Statistical significance was determined by independent sample t test. The genes having altered expression levels in drug-resistant sublines were selected and filtered by volcano plots.


Genes up/downregulated more than twofolds were selected and listed. Expression of 25 genes encoding ECM proteins (including collagen, finronectin and syndecan) and integrin receptor subunits were found to be upregulated in drug-resistant cells. In addition, expression levels of, 13 genes encoding MMPs, ADAMs, ADAMTSs and TIMPs (including MMP1, MMP9, ADAM9 and TIMP3) were found to be altered in drug-resistant sublines when compared with sensitive MCF-7.


Based on the expression analysis profiles, this report provides a preliminary insight into the relationship between drug resistance and ECM components, which are related to invasion and metastasis. Correlation of each specific ECM component with drug resistance requires further analysis.


Multidrug resistance cDNA microarray ECM Integrin MMP ADAM 



We gratefully acknowledge advises of Prof. Dr. Ali Uğur Ural and Prof. Dr. Hüseyin Avni Öktem, and METU Molecular Biology Biotechnology Research Center for technical assistance. This study was supported by TUBITAK (SBAG 3297), Turkey.


  1. 1.
    Deuchars KL, Ling V (1989) P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 16:156–165PubMedGoogle Scholar
  2. 2.
    Young AM, Allen CE, Audus KL (2003) Efflux transporters of the human placenta. Adv Drug Deliver Rev 55:125–132CrossRefGoogle Scholar
  3. 3.
    Hoyt DG, Rusnak JM, Mannix RJ, Modzelewski RA, Johnson CS, Lazo JS (1996) Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells. Cancer Res 56:4146–4149PubMedGoogle Scholar
  4. 4.
    Kraus AC, Ferber I, Bachmann SO, Specht H, Wimmel A et al (2002) In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 21:8683–8695CrossRefPubMedGoogle Scholar
  5. 5.
    Mitsumoto M, Kamura T, Kobayashi H, Sonoda T, Kaku T, Nakano H (1998) Emergence of higher levels of invasive and metastatic properties in the drug-resistant cancer cell lines after the repeated administration of cisplatin in tumor-bearing mice. J Cancer Res Clin Oncol 124:607–614CrossRefPubMedGoogle Scholar
  6. 6.
    Morin PJ (2003) Drug resistance and the microenvironment: nature and nurture. Drug Resist Updat 4:169–172CrossRefGoogle Scholar
  7. 7.
    Kars MD, Işeri OD, Gündüz U, Ural AU, Arpaci F, Molnar J (2006) Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res 26:4559–4568PubMedGoogle Scholar
  8. 8.
    Iseri ÖD, Kars MD, Eroglu S, Gündüz U (2009) Cross-resistance development and combined applications of anticancer agents in drug resistant MCF-7 cell lines. Int J Hem Oncol 1(19):1–8Google Scholar
  9. 9.
    Yilmaz R, Yücel M, Öktem HA (2008) Quality assessment of gene expression data for an affymetrix platform with the two sample t-tests statistical analysis. Int J Biotechnol Biochem 4:101–108CrossRefGoogle Scholar
  10. 10.
    Li QQ, Wang WJ, Xu JD, Cao XX, Chen Q, Yang JM, Xu ZD (2007) Up-regulation of CD147 and matrix metalloproteinase-2, -9 induced by P-glycoprotein substrates in multidrug resistant breast cancer cells. Cancer Sci 98(11):1767–1774CrossRefPubMedGoogle Scholar
  11. 11.
    Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR et al (1991) Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51(10):2720–2726PubMedGoogle Scholar
  12. 12.
    Ahmed N, Riley C, Rice G, Quinn M (2005) Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis 22(5):391–402CrossRefPubMedGoogle Scholar
  13. 13.
    Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C et al (1999) Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 6:662–668CrossRefGoogle Scholar
  14. 14.
    Nista A, Leonetti C, Bernardini G, Mattioni M, Santoni A (1997) Functional role of alpha4beta1 and alpha5beta1 integrin fibronectin receptors expressed on adriamycin-resistant MCF-7 human mammary carcinoma cells. Int J Cancer 72(1):133–141CrossRefPubMedGoogle Scholar
  15. 15.
    Narita T, Kimura N, Sato M, Matsuura N, Kannagi R (1998) Altered expression of integrins in adriamycin-resistant human breast cancer cells. Anticancer Res 18(1A):257–262PubMedGoogle Scholar
  16. 16.
    Liang Y, Meleady P, Cleary I, McDonnell S, Connolly L, Clynes M (2001) Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness. Eur J Cancer 37(8):1041–1052CrossRefPubMedGoogle Scholar
  17. 17.
    Aoudjit F, Vuori K (2001) Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 20(36):4995–5004CrossRefPubMedGoogle Scholar
  18. 18.
    Shibata K, Kikkawa F, Nawa A, Suganuma N, Hamaguchi M (1997) Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines. Cancer Res 57(23):5416–5420PubMedGoogle Scholar
  19. 19.
    Esparza J, Vilardell C, Calvo J, Juan M, Vives J, Urbano-Márquez A et al (1999) Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines A process repressed through RAS/MAP kinase signaling pathways. Blood 94(8):2754–2766PubMedGoogle Scholar
  20. 20.
    Leotlela PD, Wade MS, Duray PH, Rhode MJ, Brown HF, Rosenthal DT et al (2007) Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. Oncogene 26(26):3846–3856CrossRefPubMedGoogle Scholar
  21. 21.
    Modrowski D, Orosco A, Thévenard J, Fromigué O, Marie PJ (2005) Syndecan-2 overexpression induces osteosarcoma cell apoptosis: implication of syndecan-2 cytoplasmic domain and JNK signaling. Bone 37(2):180–189CrossRefPubMedGoogle Scholar
  22. 22.
    Orosco A, Fromigué O, Bazille C, Entz-Werle N, Levillain P, Marie PJ, Modrowski D (2007) Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma. Cancer Res 67(8):3708–3715CrossRefPubMedGoogle Scholar
  23. 23.
    Fears CY, Gladson CL, Woods A (2006) Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells. J Biol Chem 281(21):14533–14536CrossRefPubMedGoogle Scholar
  24. 24.
    Chen L, Klass C, Woods A (2004) Syndecan-2 regulates transforming growth factor-beta signaling. J Biol Chem 279(16):15715–15718CrossRefPubMedGoogle Scholar
  25. 25.
    Chaudhry SS, Cain SA, Morgan A, Dallas SL, Shuttleworth CA, Kielty CM (2007) Fibrillin-1 regulates the bioavailability of TGFbeta1. J Cell Biol 176(3):355–367CrossRefPubMedGoogle Scholar
  26. 26.
    Pupa SM, Giuffré S, Castiglioni F, Bertola L, Cantú M, Bongarzone I et al (2007) Regulation of breast cancer response to chemotherapy by fibulin-1. Cancer Res 67(9):4271–4277CrossRefPubMedGoogle Scholar
  27. 27.
    Lee YH, Albig AR, Maryann R, Schiemann BJ, Schiemann WP (2008) Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-β in mammary epithelial cells via a MMP-dependent mechanism. Carcinogenesis 29(12):2243–2251CrossRefPubMedGoogle Scholar
  28. 28.
    Han Z, Ni J, Smits P, Underhill CB, Xie B, Chen Y et al (2001) Extracellular matrix protein 1 (ECM1) has angiogenic properties and is expressed by breast tumor cells. FASEB J 15(6):988–994CrossRefPubMedGoogle Scholar
  29. 29.
    Seals DF, Courtneidge SA (2003) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17:7–30CrossRefPubMedGoogle Scholar
  30. 30.
    Lovejoy B, Welch AR, Carr S, Luong C, Broka C, Hendricks RT et al (1999) Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat Struct Biol 6:217–221CrossRefPubMedGoogle Scholar
  31. 31.
    Turton NJ, Judah DJ, Riley J, Davies R, Lipson D, Styles JA et al (2001) Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene 20(11):1300–1306CrossRefPubMedGoogle Scholar
  32. 32.
    Somerville RPT, Oblander SA, Apte SS (2003) Matrix metalloproteinases: old dogs with new tricks. Genome Biol 4(6):216CrossRefPubMedGoogle Scholar
  33. 33.
    Stefanidakis M, Koivunen E (2006) Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. Blood 108(5):1441–1450CrossRefPubMedGoogle Scholar
  34. 34.
    Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K et al (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2(10):737–744CrossRefPubMedGoogle Scholar
  35. 35.
    Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103(3):481–490CrossRefPubMedGoogle Scholar
  36. 36.
    Fischer OM, Hart S, Gschwind A, Prenzel N, Ullrich A (2004) Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Mol Cell Biol 24(12):5172–5183CrossRefPubMedGoogle Scholar
  37. 37.
    Krätzschmar J, Lum L, Blobel CP (1996) Metargidin, a membrane-anchored metalloprotease-disintegrin protein with an RGD integrin binding sequence. J Biol Chem 271(9):4593–4596CrossRefPubMedGoogle Scholar
  38. 38.
    Trochon-Joseph V, Martel-Renoir D, Mir LM, Thomaïdis A, Opolon P, Connault E et al (2004) Evidence of antiangiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin. Cancer Res 64(6):2062–2069CrossRefPubMedGoogle Scholar
  39. 39.
    Beck V, Herold H, Benge A, Luber B, Hutzler P, Tschesche H et al (2005) ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion. Int J Biochem Cell Biol 37(3):590–603CrossRefPubMedGoogle Scholar
  40. 40.
    Mochizuki S, Okada Y (2007) ADAMs in cancer cell proliferation and progression. Cancer Sci 98(5):621–628CrossRefPubMedGoogle Scholar
  41. 41.
    Liu YJ, Xu Y, Yu Q (2006) Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. Oncogene 25(17):2452–2467CrossRefPubMedGoogle Scholar
  42. 42.
    Porter S, Scott SD, Sassoon EM, Williams MR, Jones JL, Girling AC, Ball RY, Edwards DR (2004) Dysregulated expression of adamalysin-thrombospondin genes in human breast carcinoma. Clin Cancer Res 10(7):2429–2440CrossRefPubMedGoogle Scholar
  43. 43.
    Ahonen M, Baker AH, Kähäri VM (1998) Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 58(11):2310–2315PubMedGoogle Scholar
  44. 44.
    Smith MR, Kung H, Durum SK, Colburn NH, Sun Y (1997) TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytokine 9(10):770–780CrossRefPubMedGoogle Scholar
  45. 45.
    Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ et al (1998) TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 435(1):39–44CrossRefPubMedGoogle Scholar
  46. 46.
    Jiang Y, Wang M, Celiker MY, Liu YE, Sang QX, Goldberg ID, Shi YE (2001) Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Res 61(6):2365–2370PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Özlem Darcansoy Işeri
    • 1
  • Meltem Demirel Kars
    • 1
  • Fikret Arpaci
    • 2
  • Ufuk Gündüz
    • 1
  1. 1.Department of Biological SciencesMiddle East Technical UniversityAnkaraTurkey
  2. 2.Department of OncologyGülhane Military School of MedicineAnkaraTurkey

Personalised recommendations